Erythropoietin Drug Market Forecast and Opportunities: Current Technological Measures and Advancements
Market Scenario
Erythropoietin is also known as hematopoietin.
Erythropoietin is a hormone responsible for formation of red blood cells, it is
secreted by kidneys and it promotes formation of red blood cells from bone
marrow. This process is known as erythropoiesis. Erythropoietin has many
applications such as treatment of anemia, treatment of chronic kidney diseases,
AIDS and it also has applications in oncology. Synthetic forms of
erythropoietin like epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega
and epoetin delta have developed due to the development in the recombinant DNA
technology. Epoetin alfa and darbepoetin alfa are the most popular erythropoietin
drugs. They form 80% of the total Erythropoietin
Drug Market.
Amgen Inc. was the first company to invent epoetin alfa and
darbepoetin alfa. The company patented these drugs as epogen and aranesp,
respectively. Amgen’s patent for epogen has expired. This has led a lot of
companies manufacturing biosimilars to venture into the Erythropoietin drug
market. The global erythropoietin drug market is anticipated to be growing
rapidly owing to the increasing prevalence of cancer rising occurrence of
anemia and blood related disorders, patent expiration of leading
erythropoietin drugs and favorable reimbursement policies and
government regulations. According to a study published by the National
Institute of Cancer in 2016, 1,685,210 cases of cancer were registered. Most of
the cancer patients suffer from anemia which results into the rise in the need
for erythropoietin drugs. The Erythropoietin Drugs Market is expected to reach
USD 19,800.56 Million by 2030 at 11.2% CAGR during the forecast period
2022-2030.
However, high costs associated with treatment and risk of
counterfeiting are major factors that restrain the global erythropoietin drug
market.
Global Erythropoietin Drug Market –Competitive Landscape
The global erythropoietin drug market is observed to be
growing rapidly owing to increasing developments of key players like Zydus
Cadila, AstraZeneca, Takeda and GlaxoSmithKline which boosts the market
growth. The key players in the market have adopted strategy to sustain its
position in the global market through research and development and engaging in
merger and acquisitions. These players are also focusing on innovating new
therapeutic areas for the existing drugs and inventing new cost-effective
biosimilars which will in turn increase the R&D activities for the
development of erythropoietin drugs.
Teva Pharmaceutical Industries Ltd. (Israel), Hoffmann-La
Roche (Switzerland), Johnson & Johnson (US), Kyowa Hakko Kirin (Japan),
Intas Pharmaceuticals (India), Biocon (India), Emcure Pharmaceuticals (India),
Dahua Pharmaceutical (China), LG Life Sciences Ltd. (Korea), Boehringer
Ingelheim (US), BIOSIDUS (Argentina), Zydus Cadila (India), AstraZeneca (UK),
GlaxoSmithKline (UK), Takeda (Japan) are some key players in global
erythropoietin drug market.
Regional Analysis
North America has the largest market share in global
erythropoietin drug market owing to the increasing population of people
suffering from cancer and renal diseases. Additionally, technological
advancements and government funding & initiatives are boosting the growth
in this market. North America is followed by Europe. Erythropoietin drug market
in Europe is growing owing to the development of numerous biosimilars which in
turn increases the frequency of their usage. Asia Pacific is the third largest
erythropoietin drug market. It is also the fastest growing market. Middle East
and Africa is the least growing market.
Industry Updates:
·
Zydus Cadila is an Indian Pharmaceutical
company. It is also the fourth largest pharmaceutical company in India. It
produces a wide range of pharmaceuticals, herbal products, diagnostics, skin
care products and various OTC products.
·
In July 2017, Zydus Cadila, announced
that its oral molecule Zyan1 which is associated with anemia is under phase 2
trial.
·
AstraZeneca is a multinational pharmaceutical
and biopharmaceutical company. It manufactured products for chronic diseases
like cancer, cardiovascular diseases, gastrointestinal diseases, infections,
respiratory diseases, inflammations and neuroscience.
·
In January 2017, AstraZeneca in
collaboration with Fibrogen announced that its first in class drug Roxadustat
for anemia and has cleared its phase 3 trials and will be filed for approval
before the end of 2017.
·
Takeda Pharmaceutical Company is the largest
pharmaceutical company in Asia. It is also among the top 15 pharmaceutical
companies in the world. It manufactures drugs for metabolic disorders,
gastroenterology, neurology, inflammation and oncology.
·
In January 2017, Takeda in collaboration
with Akebia announced that its drug named Vadadustat is in the phase 3 of
clinical trials. Vadadustat will be an oral alternative for the injectable
erythropoietin drug.
·
GlaxoSmithKline plc is a pharmaceutical company.
It is the world’s sixth largest pharmaceutical company. It manufactures
pharmaceuticals, vaccines, oral healthcare products, nutritional products and
over the counter medicines.
·
In November 2016, GlaxoSmithKline
announced that its drug named Daprodustat, the first oral alternative for the
injectable erythropoietin drug for anemia has started with the phase 3 of
clinical trials.
Global Cardiopulmonary Resuscitation
Market Research Report—Forecast till 2027
Global Urinary Tract Infection Market
Research Report—Forecast till 2027
About US:
Market Research Future (MRFR) enable customers to unravel
the complexity of various industries through Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed
Research (CFR), and Market Research & Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013
Comments
Post a Comment